Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.
about
Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models.Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development.A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.The effect of age on the pharmacokinetics of metoprolol and its metabolitesMetoprolol pharmacokinetics and the oral contraceptive pillMetoprolol excretion into breast milk.Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Effects of ranitidine on the disposition of metoprololInvestigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon.Nebivolol: impact on cardiac and endothelial function and clinical utility.Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulationsPharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article.Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classificationThe Use of Rule-Based and QSPR Approaches in ADME Profiling: A Case Study on Caco-2 Permeability.Preliminary pharmacokinetics of streptozotocin, an antineoplastic antibiotic.Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide.Pharmacokinetics of acebutolol after intravenous bolus administration.Oros controlled-release formulations of metoprolol: an approach to the development of a system for once daily administration.Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.The fraction dose absorbed, in humans, and high jejunal human permeability relationship.Influence of site of drug delivery on the systemic availability of metoprolol: comparison of intragastric infusion and 14/190 Oros administration.Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist.Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.Influence of ranitidine on plasma metoprolol concentrations.Disposition of metoprolol in the newborn.Bioavailability of beta-adrenoceptor blocking drugs.Metabolism of metoprolol in the rat in vitro and in vivo.Segmental differences in drug permeability, esterase activity and ketone reductase activity in the albino rabbit intestine.Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients.A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.On the accuracy of calculation of the mean residence time of drug in the body and its volumes of distribution based on the assumption of central elimination.
P2860
Q31007816-C3CD50D8-733B-4343-9F4A-C6CE218E161FQ33442896-17D46E9C-A46E-4398-804E-AE67B450C0EDQ34081090-2157E8B6-B890-498D-945D-BB6F655A096FQ34273688-96880ACF-D54B-4472-9009-549228DEAC9BQ34447166-B04E991D-FAA6-4C3D-A558-5191C3098EACQ34448597-34F88A5C-ED14-42CF-9546-B1D0340E4DDEQ34511618-9A4E96EB-5E23-445A-86BB-D02A29638076Q34518682-A4786B24-80FF-41EC-8822-9984F89E95CBQ34538482-85534CC1-4F93-4371-A6F8-E8CC6CF6FA28Q34622224-FEE13C35-C672-4AA7-A66D-896000D133C1Q34622413-EF15F230-B346-4A9C-8779-F9783F46FAEAQ35846698-FE3EDC12-A81C-46D8-94F8-F9E9F9F7E21AQ36243622-AB0860E1-757F-4D81-97AF-E8C06C9C0FBFQ37906417-A669F395-5DD7-4806-A1CB-09D47FA10D24Q38677027-804513A6-EBC2-48B4-821E-28CEACD66AF1Q39205354-D23FFF5E-4EF5-4397-861A-C7BB625C7C40Q39535338-346F3977-6FAD-4A58-80BA-9F33D123DCE0Q39821483-B840154A-7150-42DC-A5F9-2F5AAC868D26Q41002347-BD8A0B73-14A9-49CD-9D3E-D0799D044FFDQ41724554-085B625E-45FF-4252-B695-D65768D98F60Q41909558-3AC112A3-BF1D-40DA-820F-40A5998CC3B4Q42006719-EE580CE1-CB34-4595-9BD7-F8363F0064ADQ42026757-7219B5A6-7264-4A16-9747-6CC6B8267E5CQ42131253-BEFAFBF9-F4A1-4227-81FB-83813A347D32Q42146560-0DC2BF67-C209-4F20-8737-638CC5F187F2Q42202239-97EFFE22-E7FD-440F-8338-A47DDB00871BQ42250442-859A8E19-01F6-419B-A25C-CC480783D688Q42407262-826365CD-593F-42A2-8836-1AE03B485649Q42802837-D501552E-1EEB-4208-895B-2AB9A0BCF3EDQ43241271-B830A1B1-5F8B-43B7-856E-DFF8305FFBB2Q43254382-5C30E25E-11C7-4B94-903C-DDADC0C48DDEQ44479922-0301941E-BC32-4350-AD19-2F48270059B5Q45963800-7160C9B7-15C1-4953-9AC8-44C91307249AQ46807643-23ACDD8E-8CE1-4AD8-9A31-91F24491402CQ47963518-1244C322-712E-491B-9F55-DB9847DD18F4Q50848458-80923BFF-567C-4922-80A4-20D571846ECC
P2860
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.
description
1974 nî lūn-bûn
@nan
1974年の論文
@ja
1974年学术文章
@wuu
1974年学术文章
@zh
1974年学术文章
@zh-cn
1974年学术文章
@zh-hans
1974年学术文章
@zh-my
1974年学术文章
@zh-sg
1974年學術文章
@yue
1974年學術文章
@zh-hant
name
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.
@en
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.
@nl
type
label
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.
@en
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.
@nl
prefLabel
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.
@en
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.
@en
P2093
P2860
P2888
P304
P356
10.1007/BF01061407
P577
1974-08-01T00:00:00Z